Ilumya

Chemical Nametildrakizumab-asmn
Dosage FormInjectable (subcutaneous; 100 mg/mL)
Drug ClassMonoclonal antibodies
SystemSkin
CompanySun Pharmaceuticals
Approval Year2018

Indication

  • Ilumya is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Last updated on 2/4/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Ilumya (tildrakizumab-asmn) Prescribing Information2018Sun Pharmaceuticals